[go: up one dir, main page]

DK2424885T3 - Sammensætninger og fremgangsmåder til behandling af lidelser, der involverer epitelcelleapoptose - Google Patents

Sammensætninger og fremgangsmåder til behandling af lidelser, der involverer epitelcelleapoptose Download PDF

Info

Publication number
DK2424885T3
DK2424885T3 DK10772573.1T DK10772573T DK2424885T3 DK 2424885 T3 DK2424885 T3 DK 2424885T3 DK 10772573 T DK10772573 T DK 10772573T DK 2424885 T3 DK2424885 T3 DK 2424885T3
Authority
DK
Denmark
Prior art keywords
cell
cells
vol
nucleic acid
disease
Prior art date
Application number
DK10772573.1T
Other languages
English (en)
Inventor
D Brent Polk
Fang Yan
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Application granted granted Critical
Publication of DK2424885T3 publication Critical patent/DK2424885T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (17)

1. LactobaciIlus-peptid omfattende et fragment af p40, hvor fragmentet omfatter SEQ ID NO:6, og hvor peptidet indeholder højst 100 aminosyrer af p40-molekylet som defineret af SEQ ID NO: 2.
2. Peptid ifølge krav 1, hvor fragmentet af p40 omfatter sekvensen SEQ ID NO: 4.
3. Peptid ifølge et hvilket som helst af de foregående krav, bestående af 32, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 eller 100 aminosyrer.
4. Peptid ifølge et hvilket som helst af de foregående krav, hvor peptidet omfatter et eller flere ikke-naturlige aminosyrer, en eller flere D-aminosyrer, et targeting-domæne eller et stabiliseringsdomæne.
5. Farmaceutisk sammensætning omfattende et Lactobacillus-peptid ifølge et hvilket som helst af kravene 1 til 4 dispergeret i en farmaceutisk acceptabel buffer, fortyndingsmiddel eller hjælpestof.
6. Isoleret og oprenset nukleinsyresegment, der koder for et Lactobacillus-peptid ifølge et hvilket som helst af kravene 1 til 4.
7. Nukleinsyresegment ifølge krav 6, yderligere omfattende en promoter, der styrer transskriptionen af nukleinsyresegmentet.
8. Nukleinsyresegment ifølge krav 7, hvor nukleinsyresegmentet er afledt af SEQ ID NO: 1.
9. Nukleinsyresegment ifølge krav 7, yderligere omfattende en replicerbar vektor, såsom et plasmid; eller en virusvektor, for eksempel en baculovirus-vektor.
10. Værtscelle omfattende et isoleret og oprenset nukleinsyresegment ifølge et hvilket som helst af kravene 6 til 9, eventuelt hvor værtscellen er en bakteriecelle, såsom en Lactobaccillus-celle, eller en eukaryotisk celle, såsom en gærcelle, eller en insektcelle.
11. Farmaceutisk sammensætning ifølge krav 5 til anvendelse til inhibering af cytokin-induceret epitelcelleapoptose og/eller fremme af epitelcellevækst hos et individ.
12. Farmaceutisk sammensætning ifølge krav 11, hvor individet yderligere behandles med et middel udvalgt blandt en EGFR-agonist eller et antibiotikum.
13. Farmaceutisk sammensætning ifølge krav 11, hvor individet er et menneske, en rotte, en mus, et får, en hund, en kat, en kanin.
14. Farmaceutisk sammensætning ifølge krav 11, hvor individet lider af (i) en gastrointestinal infektion, såsom en gastrointestinal infektion, der omfatter kolera, rotavirusinfektion eller infektion med enterotoksigen E co//; eller (ii) en gastrointestinal sygdom, såsom en gastrointestinal sygdom, der omfatter inflammatorisk tarmsygdom, irritabel tyktarm, Crohns sygdom, nekrotiserende enterokolitis, ulcerøs kolitis, cøliaki, FllV-enteropati, Helicobacter-gastritis eller NSAID-enteropati/enteritis.
15. Farmaceutisk sammensætning ifølge krav 11, hvor epitelcellen er indeholdt i hudvæv, hornhindevæv, lungevæv, et inflammeret væv, hjertevæv, muskel, et led eller cytokin-skadet væv.
16. Farmaceutisk sammensætning ifølge krav 5 til anvendelse til forebyggelse eller behandling af en gastrointestinal sygdom hos et individ.
17. Farmaceutisk sammensætning omfattende et isoleret og oprenset nukle-insyresegment ifølge krav 6, dispergeret i en farmaceutisk acceptabel buffer, fortyndingsmiddel eller hjælpestof, hvilket nukleinsyresegment er placeret under styring af en promoter, til anvendelse til forebyggelse eller behandling af en gastrointestinal sygdom hos et individ.
DK10772573.1T 2009-04-28 2010-04-28 Sammensætninger og fremgangsmåder til behandling af lidelser, der involverer epitelcelleapoptose DK2424885T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17333709P 2009-04-28 2009-04-28
PCT/US2010/032793 WO2010129347A2 (en) 2009-04-28 2010-04-28 Compositions and methods for the treatment of disorders involving epithelial cell apoptosis

Publications (1)

Publication Number Publication Date
DK2424885T3 true DK2424885T3 (da) 2016-06-06

Family

ID=43050761

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10772573.1T DK2424885T3 (da) 2009-04-28 2010-04-28 Sammensætninger og fremgangsmåder til behandling af lidelser, der involverer epitelcelleapoptose
DK16150943.5T DK3061766T3 (da) 2009-04-28 2010-04-28 Sammensætninger og fremgangsmåder til behandlingen af sygdomme der involverer epitelcelleapoptose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16150943.5T DK3061766T3 (da) 2009-04-28 2010-04-28 Sammensætninger og fremgangsmåder til behandlingen af sygdomme der involverer epitelcelleapoptose

Country Status (5)

Country Link
US (1) US8748381B2 (da)
EP (2) EP3061766B1 (da)
DK (2) DK2424885T3 (da)
ES (1) ES2568938T3 (da)
WO (1) WO2010129347A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827135B2 (en) 2015-09-15 2017-11-28 Savage Medical, Inc. Devices and methods for anchoring a sheath in a tissue cavity
US10251933B2 (en) 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
KR101992345B1 (ko) * 2017-12-29 2019-09-27 (주)메디톡스 프로모터 폴리뉴클레오티드, 신호 폴리펩티드 및 그의 용도
EP3773644A4 (en) 2018-04-06 2021-06-02 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
CN113164562A (zh) * 2018-10-19 2021-07-23 安特卫普大学 双功能肽聚糖/几丁质水解酶的抗致病活性
KR102238519B1 (ko) * 2018-12-28 2021-04-13 (주)메디톡스 외래 단백질을 발현하는 미생물, 및 그의 용도
JPWO2021167032A1 (da) * 2020-02-18 2021-08-26
CN117801080B (zh) * 2024-01-24 2024-10-22 东北农业大学 一种干酪乳杆菌细菌素及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO1992017598A1 (en) 1991-03-29 1992-10-15 The Board Of Trustees Of The University Of Illinois Production fo transgenic soybean plants
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5591616A (en) 1992-07-07 1997-01-07 Japan Tobacco, Inc. Method for transforming monocotyledons
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
WO1994002620A2 (en) 1992-07-27 1994-02-03 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1745142A4 (en) * 2004-04-20 2008-07-16 Univ Chicago PROBIOTIC COMPOUNDS FROM LACTOBACILLUS GG AND ITS USE
US9133249B2 (en) 2006-10-24 2015-09-15 Vanderbilt University Compositions and methods for the treatment of disorders involving epithelial cell apoptosis

Also Published As

Publication number Publication date
EP2424885B1 (en) 2016-03-23
WO2010129347A3 (en) 2011-03-10
US8748381B2 (en) 2014-06-10
WO2010129347A2 (en) 2010-11-11
US20120165262A1 (en) 2012-06-28
EP3061766B1 (en) 2019-12-25
EP3061766A1 (en) 2016-08-31
EP2424885A4 (en) 2012-09-26
ES2568938T3 (es) 2016-05-05
DK3061766T3 (da) 2020-03-16
EP2424885A2 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
DK2424885T3 (da) Sammensætninger og fremgangsmåder til behandling af lidelser, der involverer epitelcelleapoptose
Sturgeon et al. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases
DK2977053T3 (da) Sammensætninger og fremgangsmåder til behandling af cøliaki
Vijay-Kumar et al. Toll like receptor-5: protecting the gut from enteric microbes
Kanauchi et al. Effects of the modulation of microbiota on the gastrointestinal immune system and bowel function
NO321466B1 (no) Fremgangsmate for immunologisk pavisning av antistoffer rettet mot vevstransglutaminase (tTG), oralt farmasoytisk middel inneholdende tTG, samt anvendelse av tTG-inneholdende forbindelser.
Ellis et al. Investigation of the putative immunodominant T cell epitopes in coeliac disease
IL194987A (en) Use of PIF peptide to produce a drug to regulate the immune system
US10092623B2 (en) Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
CA2651597C (en) Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
Abbasi et al. A critical review on the gluten-induced enteropathy/celiac disease: gluten-targeted dietary and non-dietary therapeutic approaches
US20220218583A1 (en) PEPTIDE FOR TREATING SEPSIS DERIVED FROM Rv2626c PROTEIN OF MYCOBACTERIUM TUBERCULOSIS
JP2014508517A (ja) 小麦誘発過敏症診断用の小麦抗原およびペプチド
HK1228417A1 (en) Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
CN108368155A (zh) 人源性免疫抑制蛋白和肽作为药物的应用
Falcone et al. Physical and Biological Barriers at the Interface Between the Gut Microbiome and the Immune System
US20100196919A1 (en) Peptides, antibodies and fragments thereof for the treatment and diagnostic of celiac disease
JP5197887B2 (ja) イミュノグロブリン結合能を有するペプチド
Ferrari Characterization of mouse models to study the pathogenesis of celiac disease and the role played by the dysregulation of the intestinal microbiota
US20220306722A1 (en) Peptides that block presentation of antigenic islet peptides by hla-dq8 and methods for treating type-1 diabetes
FI122200B (fi) Uusia peptidejä ja menetelmiä niiden valmistamiseksi
Banerjee et al. Low dose E. coli enterotoxin for urease-based oral immunization against H. pylori in healthy volunteers: can it be safe and effective
Jones Heliobactor pylori Virulence Factors and Their Role in Pathogenesis
Jin Novel Roles of Vitamin D Receptor in Gut Microbiome and Intestinal Homeostasis
Amnuaycheewa et al. Prepared for submitting to the Journal of Proteome Research